Who Paid for the Study? How to Read Funding Lines

A fair reading method that treats the funding line as a reason to check the design rather than a reason to accept or dismiss a paper.

A study's funding line tells you who had an interest in the result, not whether the result is true. Read it as a prompt to check the design: the comparator, the primary endpoint, who ran the analysis, and whether the protocol was registered before enrollment. Funding shapes how much trust a paper earns. It does not settle the question.

What is the funding line actually telling you?

Near the end of most papers sits a block of small type. Funding. Conflicts of interest. Author contributions. Data availability. Four separate facts, printed together, easy to read as one.

• Funding source. The organization that paid for the trial itself.
• Author disclosures. Consulting fees, speaking fees, equity and advisory roles, often tied to work other than this study.
• Sponsor role. Whether the funder designed the protocol, controlled the database, ran the statistics, or had any say over publication.
• Data availability. Whether an outside group can request the raw dataset and check the arithmetic.

The last two matter more than the first. A trial with a registered protocol, an independent statistical center and a public route to the raw data is a different animal from one where the sponsor controlled every step and published a summary, even when the same manufacturer paid for both of them.

Does industry funding mean the results are wrong?

No. Methodologists have raised the same concern for years: trials paid for by a commercial sponsor report conclusions favorable to that sponsor more often than independently funded trials do. I take that seriously. The concern is rarely invented numbers. It sits in the setup: which comparator was chosen, which outcome was named primary, and how likely a disappointing trial is to be written up at all.

Now the other half of it. Large phase 3 programs in metabolic medicine cost enormous sums and take years, and in practice manufacturers are the ones who pay for them. In the STEP trials (NEJM 2021), semaglutide 2.4 mg averaged 14.9 percent of body weight over 68 weeks alongside lifestyle changes, and about one in three participants reached 20 percent or more. In SURMOUNT-1 (NEJM 2022), tirzepatide at the highest studied dose averaged about 20.9 percent over 72 weeks. Those trials studied the FDA-approved brand products, not compounded preparations. They are trial averages under trial conditions, and results vary by individual.

Both programs were funded by the companies that make those medications. Both were also registered before enrollment, monitored by an independent committee, and published with adverse events reported in detail, which is why I use them as examples of sponsor funded work done well. Refusing evidence over who paid for it leaves you nothing to reason from; accepting it without opening the protocol leaves you unable to tell a strong trial from a weak one.

Six design checks that outrank the funding line

Six questions do most of the work.

• Pre-registration. Was the trial registered before the first participant enrolled, and does the registered primary endpoint match the published one? If the two differ and nobody explains why, slow down.
• The comparator. Placebo, an older drug at a low dose, or the best available alternative at a fair dose? Beating a weak comparator is easy.
• Who analyzed the data. Named academic statisticians and an independent monitoring committee, or the sponsor alone.
• Dropouts. How many people left, why, and whether they were still counted in the primary analysis.
• Harms. Reported with the same detail as benefits, or summarized in a sentence.
• Publication history. Whether the program has ever published a trial that did not go the sponsor's way.

How is an author disclosure different from a conflict?

A long disclosure list is often the mark of a senior researcher who gets asked to advise, not of someone compromised. People who help design trials are paid for it, and the disclosure exists so you can see it and weigh it. An absent disclosure block is not automatically cleaner: no stated funder is not the same as no funder.

A patient came in last winter with a printout, funding line highlighted in yellow, ready for an argument I had no intention of having. We read the methods instead. The trial was registered, the endpoint matched, the harms ran on for pages, and by the end she was arguing with the dropout numbers rather than the sponsor, which is the better argument. I do the same thing she was doing, in my own direction. A paper that agrees with me gets checked faster than it should.

Supplement and device studies get the same six checks

They do. A pattern shows up often in that literature: the company selling the ingredient funds the work, the study is short, enrollment is small, the primary outcome is a blood marker rather than weight or a clinical event, and nothing was registered in advance. None of that means anyone acted in bad faith. It means the evidence is weak, and weak evidence should be called that no matter who paid. Applying a strict rule to pharmaceutical trials and a generous one to everything else is a common reading error: a standard that only points one way is not a standard.

What about results a clinic publishes about its own patients?

Turn the method on us. If this clinic or any other reported an average for its own patients, that number would be unblinded, have no control group, and describe only the people who stayed enrolled long enough to be counted. It could be honest and still not belong in the same sentence as a randomized trial. Wherever you see a clinic result, ask for four numbers: how many started, how many were still measured at the end, over what window, and what the comparison was.

There is something here we do not know yet. Trial averages come from trial conditions: scheduled visits, protocol driven dose escalation, participants who met entry criteria and stayed. How closely everyday care tracks those averages, and how much of any difference comes from dose escalation stopping early rather than from people stopping over cost or side effects, has not been settled by any study built to answer it. Without that data, a confident split goes past the evidence.

What does a fair verdict sound like?

Longer than a verdict. Something like this: large trial, registered before enrollment, funded by the manufacturer, analyzed by an independent statistical group, endpoint matching the registration, harms reported in full, comparator was placebo rather than an active drug, so how the benefit compares with existing treatment is still open. A prestigious journal raises the floor on a paper. It does not close the question, and neither does the funding line.

Most clinicians I know want the same conversation I do: same paper, same six questions, nobody keeping score. What I still find hard is the paper where the design is clean and the result is smaller than the person across from me was hoping for.

Written by Dr. Anjmun Sharma, MD, Medical Director, New Hope Weight Loss and Wellness.

Compounded semaglutide and compounded tirzepatide are not FDA-approved, not brand-identical, and not reviewed by the FDA for safety, effectiveness, or quality. They are prepared by state-licensed compounding pharmacies operating under section 503A after patient-specific and location-specific verification, and are dispensed only if a prescription is approved and the pharmacy can fulfill it for the patient's location, with packaging and shipping details confirmed by the pharmacy before fulfillment. Ozempic and Wegovy are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. New Hope Weight Loss and Wellness is not affiliated with or endorsed by these companies. Telehealth, prescribing and shipping depend on patient location and are confirmed before any treatment decision.

Frequently asked questions

This article is informational only and not medical advice. Speak with a licensed physician before starting or changing any GLP-1 therapy. Individual results vary. New Hope Weight Loss is a physician-supervised medical weight loss clinic in Costa Mesa, CA. Eligibility for treatment is determined during the medical consultation. Compounded semaglutide and compounded tirzepatide are not the same products as Wegovy®, Ozempic®, Mounjaro®, or Zepbound®.